Reduced Dose, Shortened Course Adjuvant Radiation Therapy for the Treatment of HPV-Associated Oropharyngeal Squamous Cell Carcinoma in Patients Who Have Undergone Transoral Robotic Surgery and Neck Dissection
This phase II trial determines the effectiveness of a reduced dose, shortened course radiation therapy (RT) regimen in preventing tumors from returning in patients with human papilloma virus (HPV)-associated oropharyngeal squamous cell cancer who have undergone transoral robotic surgery and neck dissection. Treatment options for HPV-associated oropharyngeal squamous cell carcinoma patients include either definitive chemoradiation or surgery followed by adjuvant radiation. RT uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Disease outcomes are generally favorable, with a high survival rate and good locoregional control; however, treatment-related complications can still be significant. Some of these complications can include tissue breakdown, pain and inflammation, head and neck swelling, dry mouth, taste changes, restricted mouth opening, and difficult swallowing. Giving RT at a reduced dose and shortened course following surgery may help limit these complications while also killing any remaining tumor cells.